Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

Clinical trial NCT07468916 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07468916
Sponsor: Jonsson Comprehensive Cancer Center
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Atypical Chronic Myeloid Leukemia Chronic Myelomonocytic Leukemia Myelodysplastic/Myeloproliferative Neoplasm Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified

Start date: 2026-09-29
Primary completion: 2031-09-30
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.